Literature DB >> 22027563

Bare lymphocyte syndrome: an opportunity to discover our immune system.

Dilip Shrestha1, János Szöllosi, Attila Jenei.   

Abstract

Bare lymphocyte syndrome (BLS) is a rare immunodeficiency disorder manifested by the partial or complete disappearance of major histocompatibility complex (MHC) proteins from the surface of the cells. Based on this specific feature, it is categorized into three different types depending on which type of MHC protein is affected. These proteins are mainly involved in generating the effective immune responses by differentiating 'self' from 'non-self' antigens through a process referred to as antigen presentation. Investigations on BLS have immensely contributed to our understanding of the transcriptional regulation of these molecules and have led to the discovery of several important proteins of the antigen presentation pathway. Reviews on this subject consistently project type II BLS, MHC II deficiency as BLS syndrome, although literatures' document cases of other types of BLS too. Therefore, in this article, we have assembled information on the BLS syndrome to produce a systematic narration while emphasizing the importance of BLS system in studying various aspects of immune biology.
Copyright © 2011 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22027563     DOI: 10.1016/j.imlet.2011.10.007

Source DB:  PubMed          Journal:  Immunol Lett        ISSN: 0165-2478            Impact factor:   3.685


  5 in total

1.  A novel spontaneous mutation in the TAP2 gene unravels its role in macrophage survival.

Authors:  Antonio Lapenna; Ibrahim Omar; Michael Berger
Journal:  Immunology       Date:  2017-01-19       Impact factor: 7.397

Review 2.  HLA variation and disease.

Authors:  Calliope A Dendrou; Jan Petersen; Jamie Rossjohn; Lars Fugger
Journal:  Nat Rev Immunol       Date:  2018-01-02       Impact factor: 53.106

3.  Family History of Early Infant Death Correlates with Earlier Age at Diagnosis But Not Shorter Time to Diagnosis for Severe Combined Immunodeficiency.

Authors:  Anderson Dik Wai Luk; Pamela P Lee; Huawei Mao; Koon-Wing Chan; Xiang Yuan Chen; Tong-Xin Chen; Jian Xin He; Nadia Kechout; Deepti Suri; Yin Bo Tao; Yong Bin Xu; Li Ping Jiang; Woei Kang Liew; Orathai Jirapongsananuruk; Tassalapa Daengsuwan; Anju Gupta; Surjit Singh; Amit Rawat; Amir Hamzah Abdul Latiff; Anselm Chi Wai Lee; Lynette P Shek; Thi Van Anh Nguyen; Tek Jee Chin; Yin Hsiu Chien; Zarina Abdul Latiff; Thi Minh Huong Le; Nguyen Ngoc Quynh Le; Bee Wah Lee; Qiang Li; Dinesh Raj; Mohamed-Ridha Barbouche; Meow-Keong Thong; Maria Carmen D Ang; Xiao Chuan Wang; Chen Guang Xu; Hai Guo Yu; Hsin-Hui Yu; Tsz Leung Lee; Felix Yat Sun Yau; Wilfred Hing-Sang Wong; Wenwei Tu; Wangling Yang; Patrick Chun Yin Chong; Marco Hok Kung Ho; Yu Lung Lau
Journal:  Front Immunol       Date:  2017-07-12       Impact factor: 7.561

4.  Suppression of Non-Random Fertilization by MHC Class I Antigens.

Authors:  Junki Kamiya; Woojin Kang; Keiichi Yoshida; Ryota Takagi; Seiya Kanai; Maito Hanai; Akihiro Nakamura; Mitsutoshi Yamada; Yoshitaka Miyamoto; Mami Miyado; Yoko Kuroki; Yoshiki Hayashi; Akihiro Umezawa; Natsuko Kawano; Kenji Miyado
Journal:  Int J Mol Sci       Date:  2020-11-19       Impact factor: 5.923

5.  FOXP1 suppresses immune response signatures and MHC class II expression in activated B-cell-like diffuse large B-cell lymphomas.

Authors:  P J Brown; K K Wong; S L Felce; L Lyne; H Spearman; E J Soilleux; L M Pedersen; M B Møller; T M Green; D M Gascoyne; A H Banham
Journal:  Leukemia       Date:  2015-10-26       Impact factor: 11.528

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.